Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month High - Still a Buy?

Key Points

• Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reached a new 52-week high of $36.74 on recent trading, closing at $36.57, with a trading volume of 549,446 shares.
• Several Wall Street analysts have given positive outlooks for Kiniksa Pharmaceuticals, including a raise of the target price by Wells Fargo from $30 to $42, and a strong-buy rating upgrade by Wall Street Zen.
• Insider trading has been notable, with COO Eben Tessari selling over 13,000 shares, indicating potential profit-taking amidst the stock's recent performance.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) shares hit a new 52-week high during trading on Tuesday . The stock traded as high as $36.74 and last traded at $36.57, with a volume of 549446 shares traded. The stock had previously closed at $35.71.

Analysts Set New Price Targets

Several analysts recently commented on KNSA shares. Jefferies Financial Group raised their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 7th. Finally, Wells Fargo & Company raised their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Stock Up 0.2%

The stock's 50-day moving average is $31.86 and its 200-day moving average is $27.18. The firm has a market cap of $2.75 billion, a P/E ratio of 927.73 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Michael R. Megna sold 11,000 shares of the company's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $34.84, for a total value of $383,240.00. Following the sale, the chief accounting officer owned 38,011 shares of the company's stock, valued at approximately $1,324,303.24. This represents a 22.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ross Moat sold 3,523 shares of the company's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $35.31, for a total transaction of $124,397.13. Following the completion of the sale, the insider directly owned 9,415 shares in the company, valued at approximately $332,443.65. The trade was a 27.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 562,271 shares of company stock worth $18,716,309 in the last quarter. 53.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds have recently added to or reduced their stakes in KNSA. Northern Trust Corp grew its holdings in Kiniksa Pharmaceuticals International by 11.1% during the 4th quarter. Northern Trust Corp now owns 283,599 shares of the company's stock worth $5,610,000 after acquiring an additional 28,393 shares during the last quarter. Bank of America Corp DE lifted its position in Kiniksa Pharmaceuticals International by 2.2% during the 4th quarter. Bank of America Corp DE now owns 215,772 shares of the company's stock valued at $4,268,000 after purchasing an additional 4,654 shares during the period. Balyasny Asset Management L.P. acquired a new position in Kiniksa Pharmaceuticals International during the 4th quarter valued at about $256,000. Deutsche Bank AG lifted its position in Kiniksa Pharmaceuticals International by 77.3% during the 4th quarter. Deutsche Bank AG now owns 142,397 shares of the company's stock valued at $2,817,000 after purchasing an additional 62,083 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International during the 4th quarter valued at about $61,000. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.